Defining the "S" in SERMs
- 29 March 2002
- journal article
- editorial
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 295 (5564) , 2380-2381
- https://doi.org/10.1126/science.1070442
Abstract
Tamoxifen, which opposes estrogen action in some tissues while mimicking its action in others, has reduced breast cancer mortality significantly during the past decade. In their Perspective, Katzenellenbogen and Katzenellenbogen discuss new findings (Shang and Brown) that unravel the molecular basis of tamoxifen's differential activity in breast and uterine tissue.Keywords
This publication has 15 references indexed in Scilit:
- Molecular Determinants for the Tissue Specificity of SERMsScience, 2002
- Genetic Ablation of the Steroid Receptor Coactivator-Ubiquitin Ligase, E6-AP, Results in Tissue-Selective Steroid Hormone Resistance and Defects in ReproductionMolecular and Cellular Biology, 2002
- Structure‐Function Relationships in Estrogen Receptors and the Characterization of Novel Selective Estrogen Receptor Modulators with Unique Pharmacological ProfilesAnnals of the New York Academy of Sciences, 2001
- Coregulator Codes of Transcriptional Regulation by Nuclear ReceptorsJournal of Biological Chemistry, 2001
- Selective coactivation of estrogen-dependent transcription by CITED1 CBP/p300-binding proteinGenes & Development, 2001
- The Multifaceted Mechanisms of Estradiol and Estrogen Receptor SignalingJournal of Biological Chemistry, 2001
- Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs)Trends in Molecular Medicine, 2001
- The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland developmentProceedings of the National Academy of Sciences, 2000
- Tamoxifen in the Treatment of Breast CancerNew England Journal of Medicine, 1998
- Partial Hormone Resistance in Mice with Disruption of the Steroid Receptor Coactivator-1 (SRC-1) GeneScience, 1998